Updated Phase I Results of Carboplatin, Pemetrexed and Exemestane in Postmenopausal Women with Metastatic Non-Squamous NSCLC

被引：0
|
作者：
Young, P. [1 ]
Marquez, D. [1 ]
Noor, Z. [1 ]
Callahan, R. [1 ]
Jones, B. [1 ]
Wong, D. [1 ]
Goldman, J. W. [1 ]
Applebaum, S. [1 ]
Rausch, R. [1 ]
Yanes, C. [1 ]
Bueno, S. [1 ]
Garban, N. [1 ]
Elashoff, D. [2 ]
Garon, E. [3 ]
Pietras, R. [4 ]
机构：
[1] Univ Calif Los Angeles, Hematol Oncol, Santa Monica, CA USA
[2] Univ Calif Los Angeles, Med, Los Angeles, CA USA
[3] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA
[4] Univ Calif Los Angeles, David Geffen Sch Med, Med Hematol Oncol, Los Angeles, CA 90095 USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 10期
关键词：
estrogen receptor; Exemestane; NSCLC;
D O I：
10.1016/j.jtho.2018.08.661
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.01-104
引用
收藏
页码：S504 / S504
页数：1
相关论文
共 50 条
  • [1] A Phase I Study of Exemestane with Carboplatin and Pemetrexed in Postmenopausal Women with Metastatic, Non-Squamous Non-Small Cell Lung Cancer
    Pietras, Richard
    Goldman, Jonathan W.
    Marquez-Garban, Diana C.
    Wong, Deborah J. L.
    Applebaum, Steven
    Mendenhall, Melody
    Ledezma, Blanca A.
    Wolf, Brian
    Adame, Carlos R.
    Rosales, Sarah
    Paroly, Jill
    Paiz, Sebastian
    Nameth, Danielle
    Spiegel, Marshall L.
    Hecht, Naomi
    Brennan, Meghan
    Dubinett, Steven M.
    Garon, Edward B.
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S667 - S667
  • [2] A Phase II Trial of Tiragolumab with Carboplatin, Pemetrexed, And Atezolizumab in Non-Squamous NSCLC and Brain Metastases
    Schluger, B.
    Burns, T. F.
    Wang, H.
    Petro, D. P.
    Ohr, J.
    Burton, S. A.
    McCall, N.
    Choi, S.
    Abdullah, K. G.
    Niranjan, A.
    Hadjipanayis, C. G.
    Villaruz, L. C.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S393 - S394
  • [3] Prevalence, Onset, and Severity of Renal Impairment With Pemetrexed/Carboplatin plus /- Pembrolizumab in Metastatic Non-Squamous NSCLC
    Miller, J.
    Brown, B.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1084 - S1084
  • [4] Phase I/II Study of Erlotinib, Carboplatin, Pemetrexed and Bevacizumab for Advanced Non-Squamous NSCLC Harboring EGFR Mutation
    Yokoi, Takashi
    Kurata, Takayasu
    Torii, Yoshitaro
    Satsutani, Naoko
    Kibata, Kayoko
    Niki, Maiko
    Nomura, Shosaku
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1219 - S1219
  • [5] A Phase II Study of Pemetrexed plus Carboplatin Followed by Maintenance Pemetrexed in Elderly Patients with Advanced Non-Squamous NSCLC
    Tamiya, Motohiro
    Tamiya, Akihiro
    Kaneda, Hiroyasu
    Nakagawa, Kazuhiko
    Goto, Koichi
    Yoh, Kiyotaka
    Okamoto, Hiroaki
    Shimokawa, Tsuneo
    Tanaka, Hiroshi
    Abe, Tetsuya
    Daga, Haruko
    Takeda, Koji
    Hirashima, Tomonori
    Atagi, Shinji
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S316 - S316
  • [6] A Phase I/Ib Study of Binimetinib (MEK162), a MEK Inhibitor Plus Carboplatin/Pemetrexed in Non-Squamous NSCLC
    Graham, D.
    Chen, E.
    Pisters, K.
    Bradbury, P.
    Trinkaus, M.
    Chan, M.
    Arif, S.
    Zurawska, U.
    Rothenstein, J.
    Zawisza, D.
    Effendie, S.
    Sawczak, M.
    Leighl, N.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S481 - S482
  • [7] A Phase I Study of Apatinib Combined with Pemetrexed and Carboplatin in Untreated EGFR-Negative Stage IV Non-Squamous NSCLC
    Huang, M.
    Gong, Y.
    Zhu, J.
    Qin, Y.
    Peng, F.
    Ren, L.
    Ding, Z.
    Liu, Y.
    Wang, Y.
    Lu, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (12) : S1072 - S1072
  • [8] Tivantinib in combination with Carboplatin and Pemetrexed as first line treatment in patients with advanced non-squamous NSCLC or Malignant Pleural Mesothelioma: results of phase I trial
    Zucali, P. A.
    Simonelli, M.
    De Vincenzo, F.
    Fatuzzo, G.
    Bertossi, M.
    Perrino, M.
    Miggiano, C.
    Giordano, L.
    Bonifacio, C.
    Sposta, F. Mrakic
    Santoro, A.
    ANNALS OF ONCOLOGY, 2015, 26 : 78 - 78
  • [9] Phase II study of carboplatin/ pemetrexed/bevacizumab for non-squamous NSCLC with carcinomatous pleuritis (NEJ013A)
    Miyauchi, Eisaku
    Usui, Kazuhiro
    Sugawara, Shunichi
    Nishitsuji, Masaru
    Fujita, Yuka
    Mouri, Atsuto
    Watanabe, Hiroshi
    Sakai, Hiroshi
    Kinoshita, Ichiro
    Hagiwara, Koichi
    ANNALS OF ONCOLOGY, 2016, 27
  • [10] Pemetrexed-Carboplatin Versus Paclitaxel (Weekly)-Carboplatin as First Line Chemotherapy in Advanced Non-Squamous NSCLC
    Malik, P.
    Yadav, A.
    Jain, D.
    Pathy, S.
    Mohan, A.
    Khurana, S.
    Kumar, S.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S354 - S355
12345